Molecular Staging Overview
- Year Founded
-
1998
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$35.2M
Molecular Staging General Information
Description
Developer of technologies for the detection and measurement of proteins and nucleic acids. The company provides technologies for proteomics, genomics, pharmacogenomics and diagnostics applications. The company develops Whole Genome Amplification (WGA) technology which is designed to eliminate limitations created by scarce quantities of DNA samples.
Contact Information
Website
www.molecularstaging.comCorporate Office
- 300 George Street
- New Haven, CT 06511
- United States
Corporate Office
- 300 George Street
- New Haven, CT 06511
- United States
Molecular Staging Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 27-Sep-2004 | $35.2M | Completed | Generating Revenue | ||
| 5. Grant | 08-Oct-2001 | Completed | ||||
| 4. Later Stage VC (Series D) | Completed | Generating Revenue | ||||
| 3. Later Stage VC (Series C) | 06-Nov-2000 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 04-Feb-1999 | $5.17M | $18.7M | Completed | Product Development | |
| 1. Early Stage VC (Series A) | 01-Jan-1998 | $13.5M | $13.5M | Completed | Product Development |
Molecular Staging Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C2 | ||||||||
| Series C1 | ||||||||
| Series B | 700,000 | $0.010000 | $7.38 | $7.38 | 1x | $7.38 | 3.4% | |
| Series A | 4,500,000 | $0.010000 | $0.24 | $3 | $3 | 1x | $3 | 21.87% |
Molecular Staging Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Molecular Staging Patents
Molecular Staging Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-1585833-A2 | Rolling circle amplification of rna | Active | 31-Dec-2002 | ||
| EP-1585833-A4 | Rolling circle amplification of rna | Active | 31-Dec-2002 | ||
| AU-2003293023-A8 | Chemokine parc suppresses specific cytokine production | Inactive | 26-Nov-2002 | ||
| AU-2003293023-A1 | Chemokine parc suppresses specific cytokine production | Inactive | 26-Nov-2002 | ||
| US-20040101510-A1 | Anticancer agents; antiarthritic agents; antiproliferative agents; measurement protein, calibration cell proliferation | Inactive | 26-Nov-2002 | A61K38/195 |
Molecular Staging Former Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CHL Medical Partners | Venture Capital | Minority | ||
| CIBC Capital Partners | Investment Bank | Minority | ||
| Cooper Hill Partners | Hedge Fund | Minority | ||
| Domain Associates | Venture Capital | Minority | ||
| Investor | PE/Buyout | Minority |
Molecular Staging FAQs
-
When was Molecular Staging founded?
Molecular Staging was founded in 1998.
-
Where is Molecular Staging headquartered?
Molecular Staging is headquartered in New Haven, CT.
-
What industry is Molecular Staging in?
Molecular Staging’s primary industry is Biotechnology.
-
Is Molecular Staging a private or public company?
Molecular Staging is a Private company.
-
What is the current valuation of Molecular Staging?
The current valuation of Molecular Staging is .
-
What is Molecular Staging’s current revenue?
The current revenue for Molecular Staging is .
-
How much funding has Molecular Staging raised over time?
Molecular Staging has raised $73.9M.
-
Who are Molecular Staging’s investors?
CHL Medical Partners, CIBC Capital Partners, Cooper Hill Partners, Domain Associates, and Investor are 5 of 8 investors who have invested in Molecular Staging.
-
When was Molecular Staging acquired?
Molecular Staging was acquired on 27-Sep-2004.
-
Who acquired Molecular Staging?
Molecular Staging was acquired by Qiagen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
